These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26111238)

  • 1. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children.
    Li-Kim-Moy J; Yin JK; Rashid H; Khandaker G; King C; Wood N; Macartney KK; Jones C; Booy R
    Euro Surveill; 2015 Jun; 20(24):. PubMed ID: 26111238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies.
    Kaczmarek MC; Duong UT; Ware RS; Lambert SB; Kelly HA
    Vaccine; 2013 Nov; 31(46):5359-65. PubMed ID: 24055353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.
    Dey A; Gidding HF; Menzies R; McIntyre P
    Vaccine; 2014 Apr; 32(19):2204-8. PubMed ID: 24613527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB; Chuk LM; Nissen MD; Nolan TM; McVernon J; Booy R; Heron L; Richmond PC; Walls T; Marshall HS; Reynolds GJ; Hartel GF; Hu W; Lai MH
    Influenza Other Respir Viruses; 2013 Sep; 7(5):676-85. PubMed ID: 23551933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H; Poole T; Turner N; Reynolds G
    Vaccine; 2012 Jul; 30(33):4945-52. PubMed ID: 22664224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under.
    Petousis-Harris H; Poole T; Booy R; Turner N
    Vaccine; 2011 Apr; 29(16):2933-7. PubMed ID: 21338679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events associated with 2010 CSL and other inactivated influenza vaccines.
    Kelly HA; Skowronski DM; De Serres G; Effler PV
    Med J Aust; 2011 Sep; 195(6):318-20. PubMed ID: 21929484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC; Currie AJ; Wiertsema SP; Conway N; Kirkham LA; Fuery A; Mascaro F; Geelhoed GC; Richmond PC
    Vaccine; 2011 Jul; 29(32):5107-13. PubMed ID: 21640152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.
    Stockwell MS; Broder K; LaRussa P; Lewis P; Fernandez N; Sharma D; Barrett A; Sosa J; Vellozzi C
    JAMA Pediatr; 2014 Mar; 168(3):211-9. PubMed ID: 24395025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children.
    Sawlwin DC; Graves Jones A; Albano FR
    Vaccine; 2019 Apr; 37(18):2447-2454. PubMed ID: 30935743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Aug; 59(31):989-92. PubMed ID: 20703207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A; Carcione D; Richmond PC; Jacoby P; Effler PV
    Vaccine; 2011 Oct; 29(45):7920-4. PubMed ID: 21864621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008].
    Wang X; Liu Y; Zhao YW
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):443-6. PubMed ID: 20084973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.
    Halasa NB; Gerber MA; Berry AA; Anderson EL; Winokur P; Keyserling H; Eckard AR; Hill H; Wolff MC; McNeal MM; Edwards KM; Bernstein DI
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):214-24. PubMed ID: 26334249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.